AMG.XETRA Amgen Inc.

Healthcare Pharmaceuticals XETRA Stock Exchange
418.15 EUR
Close of Nov 5, 2026
262.22 438.75
Market cap
EUR 226B
P/E
28.2x
P/B
17.88x
ROE
76.7%
Dividend yield
2.12%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is AMG.XETRA undervalued?

Graham number

The Graham number of Amgen Inc. cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Amgen Inc. fundamental analysis

No fundamental analysis for Amgen Inc. yet.

Amgen Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Amgen Inc.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which re…

Full company profile